# Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk

Study · id `cardio:ct-nct02991118` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02991118](<https://clinicaltrials.gov/study/NCT02991118>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02991118

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 779 participants.

## Technical summary

Registry record NCT02991118. Randomized; triple masking; primary purpose treatment. Start 2016-11-18 (actual); primary completion 2018-08-22 (actual). Results posted on 2020-04-27.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 779 participants (enrolled count; ClinicalTrials.gov record NCT02991118, source copy `cardio:ctgov-nct02991118-2020-04-27`, retrieved 2026-10-31)
- Started: 2016-11-18 (actual) (ClinicalTrials.gov record NCT02991118, source copy `cardio:ctgov-nct02991118-2020-04-27`, retrieved 2026-10-31)
- Primary completion: 2018-08-22 (actual) (ClinicalTrials.gov record NCT02991118, source copy `cardio:ctgov-nct02991118-2020-04-27`, retrieved 2026-10-31)
- Completion: 2018-08-22 (actual) (ClinicalTrials.gov record NCT02991118, source copy `cardio:ctgov-nct02991118-2020-04-27`, retrieved 2026-10-31)
- Results first posted: 2020-04-27 (ClinicalTrials.gov record NCT02991118, source copy `cardio:ctgov-nct02991118-2020-04-27`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT02991118, source copy `cardio:ctgov-nct02991118-2020-04-27`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02991118-2020-04-27`, retrieved 2026-10-31)

## The registry's words

- Brief title: Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk
- Acronym: CLEAR Wisdom
- Condition: Hypercholesterolemia
- Condition: Atherosclerotic Cardiovascular Disease
- Intervention (Drug): bempedoic acid
- Intervention (Drug): placebo
- Lead sponsor: Esperion Therapeutics, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Bempedoic acid (`cardio:bempedoic-acid`)
- Registry lists this organization as the lead sponsor: Esperion Therapeutics, Inc. (`cardio:org-esperion-therapeutics-inc`)

## Provenance

Content hash: e9cbbfa71872a43fc91b8931f121f86f800cd2aab74234fb06bca98ef6d3049c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
